Heron Therapeutics, Inc. (0J4V.L)
| Previous close | 2.8300 |
| Open | 2.6600 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 2.5500 - 2.6789 |
| 52-week range | 0.5424 - 3.1950 |
| Volume | |
| Avg. volume | 12,412 |
| Market cap | 2.032M |
| Beta (5Y monthly) | 1.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.2930 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireHeron Therapeutics to Host Investor Day on May 15, 2024 in New York City
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on Wednesday, May 15, 2024 in New York City, beginning at 9:30 am ET. The event will include presentations from members of the Company's leadership team highlighting the renewed focus across the Acute Care and Oncology franchises and panel discussions featuring patient and physician experience with Heron's commercial products. The presentations will also include up
- PR Newswire
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024, at 11:00 AM ET at the 23rd Annual Needham Virtual Healthcare Conference. The conference is being held in a virtual format, April 8-11, 2024.
Simply Wall St.Heron Therapeutics Full Year 2023 Earnings: Beats Expectations
Heron Therapeutics ( NASDAQ:HRTX ) Full Year 2023 Results Key Financial Results Revenue: US$127.0m (up 18% from FY...
